The U.S. Centers for Medicare and Medicaid Services (CMS) said on Wednesday that it would seek “greater transparency” in drug price negotiations under President Donald Trump’s administration. The statement follows criticism from the pharmaceutical industry regarding the program.
The U.S. Centers for Medicare and Medicaid Services (CMS) said on Wednesday that it would seek “greater transparency” in drug price negotiations under President Donald Trump’s administration. The statement follows criticism from the pharmaceutical industry regarding the program.Read more…